Simplify Logo

Full-Time

Senior Bioinformatics Scientist

Solid Tumor DNA Oncology

Updated on 9/3/2024

Tempus

Tempus

1,001-5,000 employees

AI-driven healthcare data analysis platform

Data & Analytics
Hardware
AI & Machine Learning
Financial Services
Biotechnology
Healthcare

Compensation Overview

$140k - $180kAnnually

+ Incentive Compensation + Restricted Stock Units

Senior, Expert

San Carlos, CA, USA

Category
Bioinformatics
Biology & Biotech
Required Skills
Python
R
Data Structures & Algorithms
Requirements
  • Experience with scientific programming, relational data systems, algorithms development, data modeling, and statistical modeling.
  • Leadership experience in NGS pipeline development in a clinical setting.
  • Must have completed a Ph.D. in Cancer Biology or Molecular Biology related to cancer.
  • At least 5+ years of post-doc experience.
  • Computational skills using Python and/or R.
Responsibilities
  • Design and conduct analysis to improve variant calling, classification, and analysis systems.
  • Translate insight from model systems into predictors and classifiers of therapeutic response and prognosis in clinical cancer care.
  • Lead collaborations with scientists, and clinicians to design and perform analyses on cancer clinical sequencing data in order to improve quality of care.
  • Lead an interdisciplinary group of scientists and engineers to translate research into clinically actionable insights for our clients.
  • Develop algorithms used to gain insight into cancer variation through analysis of next-generation sequencing data.
  • Communicate with outside scientific teams as well as product and bioinformatics leadership.
  • Produce high-quality and detailed documentation for all projects.
  • Provide thought leadership and technical expertise for analytical and clinical validation experiments and reports.
  • Plan, review, and guide team members' contributions toward best practices and organizational goals.

Tempus focuses on enhancing patient outcomes through the use of data and artificial intelligence in the healthcare sector. The company offers a platform that analyzes medical data, helping physicians make better treatment decisions by providing insights from medical images and identifying care gaps. For pharmaceutical and biotech companies, Tempus aids in drug development by discovering new targets and assessing treatment effectiveness. Patients benefit from personalized therapy options identified through the platform. Tempus conducts significant research, particularly in cancer, and has developed tools like a pan-cancer organoid platform and a liquid biopsy assay for profiling circulating tumor DNA. The company generates revenue by charging healthcare providers and companies for access to its platform and insights.

Company Stage

Series G

Total Funding

$1.3B

Headquarters

Chicago, Illinois

Founded

2015

Growth & Insights
Headcount

6 month growth

5%

1 year growth

12%

2 year growth

36%
Simplify Jobs

Simplify's Take

What believers are saying

  • Tempus's IPO and significant revenue generation indicate strong financial health and growth potential.
  • Collaborations with industry giants like SoftBank and United Therapeutics can lead to groundbreaking advancements and increased market share.
  • The company's focus on personalized therapy and AI-driven insights can significantly improve patient outcomes, making it a rewarding place to work for those passionate about healthcare innovation.

What critics are saying

  • The lawsuit from Guardant Health over patent infringement could result in financial and reputational damage.
  • Operating in a highly competitive market with peers like Foundation Medicine and Guardant Health requires continuous innovation to maintain a competitive edge.

What makes Tempus unique

  • Tempus leverages AI to provide actionable insights from medical data, setting it apart from competitors who may not integrate AI as deeply into their platforms.
  • Their focus on personalized therapy options and extensive cancer research, including a pan-cancer organoid platform and liquid biopsy assay, distinguishes them in the healthcare tech space.
  • Tempus's collaboration with major firms like SoftBank and United Therapeutics highlights its strong industry partnerships and credibility.